After an epic battle of blockbusters, Merck leapfrogs Bristol-Myers to take the lead on PD-1/L1 market

Merck did it.

In one of the most intense commercial and research development rivalries in biopharma history, Merck’s Keytruda has edged ahead of Bristol-Myers Squibb’s Opdivo for the first time since the showdown got started nearly 4 years ago.